Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zenas BioPharma (ZBIO) Income from Continuing Operations (2023 - 2025)

Zenas BioPharma has reported Income from Continuing Operations over the past 3 years, most recently at 148067000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 148067000.0 for Q4 2025, up 361.91% from a year ago — trailing twelve months through Dec 2025 was 10772000.0 (up 106.69% YoY), and the annual figure for FY2025 was 10772000.0, up 106.68%.
  • Income from Continuing Operations for Q4 2025 was 148067000.0 at Zenas BioPharma, up from 51499000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for ZBIO hit a ceiling of 148067000.0 in Q4 2025 and a floor of 56534000.0 in Q4 2024.
  • Median Income from Continuing Operations over the past 3 years was 35775000.0 (2024), compared with a mean of 13930000.0.
  • Biggest five-year swings in Income from Continuing Operations: tumbled 208.37% in 2024 and later surged 361.91% in 2025.
  • Zenas BioPharma's Income from Continuing Operations stood at 24779000.0 in 2023, then plummeted by 128.15% to 56534000.0 in 2024, then surged by 361.91% to 148067000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 148067000.0 (Q4 2025), 51499000.0 (Q3 2025), and 52223000.0 (Q2 2025) per Business Quant data.